Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201168 | PMC |
| http://dx.doi.org/10.1177/25158414231173533 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The multiprobe: a revolutionary concept for vitreoretinal surgery.
Ther Adv Ophthalmol
May 2023
Vitreoretinal Surgery Division, Department of Ophthalmology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry.
J Pharm Biomed Anal
June 2002
Department of Drug Metabolism and Pharmacokinetics, Novartis Institute for Biomedical Research, East Hanover, NJ 07936, USA.
Signal Transduction Inhibitor 571 (STI571, formerly known as CGP 57148B) or Gleevec received fast track approval by the US Food and Drug Administration (FDA) for treatment of chronic myeloid leukemia (CML). STI571 (Gleevec) is a revolutionary and promising new oral therapy for CML, which functions at the molecular level with high specificity. The dramatic improvement in efficacy compared with existing treatments prompted an equally profound increase in the pace of development of Gleevec.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!